2024-05-24 16:08:27 ET
Summary
- XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke.
- Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis.
- While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
- The True Human "Antibody" technology platform is versatile, in that it can be used to target a wide range of disorders like cancer, stroke, heart attack, arthritis and much more.
XBiotech Inc. ( XBIT ) has been able to complete recruitment for a few studies already, and it has initiated another one targeting patients with Rheumatoid arthritis [RA]. Natrunix is being developed to treat patients with RA and pancreatic cancer. Hutrukin is being advanced to help patients with stroke....
Read the full article on Seeking Alpha
For further details see:
XBiotech: Several Shots On Goal In Big Target Market Indications